The Valley Desk

Clinical trial reportCell reports. MedicinePublished

Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Bristol Myers Squibb. Affiliation source

Publication record

Type
Clinical trial report
Venue
Cell reports. Medicine
Published
Subject terms
T-Lymphocytes; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Recurrence; Thalidomide; Ubiquitin-Protein Ligases; Adaptor Proteins, Signal Transducing; Drug Resistance, Neoplasm; Aged; Middle Aged; Female
PubMed ID
38776914
PubMed Central ID
PMC11228401
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal